Noblis Secures Space in New NASA Contract

Montana Patent of the Month - June 2021

Noblis, Inc. has been selected as a key teammate on a new NASA Academic Mission Services 2 (NAMS-2) contract. The five-year, $121 million contract is being led by Crown Consulting, Inc. with plans to provide aerospace and technology research and development (R&D) support for NASA’s Ames Research Center.

“We are excited to join this collaborative team of experts across government, industry and academia,” said Mile Corrigan, Noblis’ president and CEO. “Noblis’ commitment to innovation and excellence aligns with NASA’s goal to advance new technologies from R&D to mission ready.”

Noblis has experience across a broad spectrum of industries and has previously worked with a wide range of government clients in the defense, homeland security, intelligence, law enforcement and federal civil sectors.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Zephyr AI: Pioneering the Future of Precision Medicine

Alaska Patent of the Month - September 2021

In the dynamic world of healthcare, a McLean-based startup, Zephyr AI, is making waves with its groundbreaking approach to precision medicine and a newly successful funding round. Established in 2020, Zephyr AI is on a mission to democratize personalized treatment by harnessing the power of artificial intelligence (AI) to extract meaningful insights from complex healthcare data.

Zephyr AI’s innovative algorithms aim to address a pressing need in the medical field: the ability to deliver precise, individualized treatments without waiting for the next generation of high-fidelity data. As Jeff Sherman, co-founder and interim CEO, emphasizes, the company operates with a sense of urgency to provide solutions for patients today.

Precision medicine, the focus of Zephyr AI, tailors medical management decisions to the unique genomic, environmental, and lifestyle factors of each patient. This approach promises to transform the treatment landscape for diseases such as cancer and heart disease by offering targeted and effective therapies.

In a significant milestone, Zephyr AI secured $111 million in a Series A funding round in March, attracting investments from prominent entities like Revolution Growth and Eli Lilly & Co. This funding is set to accelerate the development of their AI-driven algorithms and expand their capacity to analyze vast datasets for more nuanced medical insights.

The company was co-founded by industry visionaries Grant Verstandig and Yisroel Brumer, who bring a wealth of experience from healthcare and defense sectors. Under their leadership, Zephyr AI is gearing up to significantly expand its team, particularly in science, engineering, and business development.

A key factor in Zephyr AI’s success has been its ability to demonstrate the real-world effectiveness of its algorithms. During investor demos, the company showcased how their technology can distinguish between patients with similar clinical profiles who respond differently to treatments. This capability underscores the potential of AI to revolutionize personalized medicine by ensuring that patients receive the most effective therapies based on their unique characteristics.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

How Virginia’s State R&D Tax Credits are Changing

ETRAK Technologies to Compete for $75K in Funding from Alabama Launchpad

Virginia’s R&D tax credit has recently undergone some statutory changes which alter how these credits are calculated and how they are funded.

The state actually has two different R&D credits for taxpayers conducting R&D. With these new changes, some businesses will benefit while others will be negatively impacted. Either way, the new funding change also expands the tax planning opportunities around the credit, so it is important for taxpayers to understand how they will be impacted.

April 11, 2024, Virginia signed a new law that modifies credit caps and calculation processes for the state’s R&D tax credits in an effort to prioritize benefits for smaller companies.

Virginia R&D Credit Regimes

The state offers two different credits:

  • The Research and Development Expenses Tax Credit (RDC) – a refundable credit
  • The Major Research and Development Expenses Tax Credit (MRD) – a nonrefundable credit

Taxpayers must submit an application each year to the state. The state reviews all applications and allocates set pools of money to qualified applicants based on the yearly aggregate credit cap. This means that any qualifying company may not even receive the full benefit of their credit if many other companies are also applying.

Historically, the primary differences between these credits revolved around the total qualified research expenses (QREs) the taxpayer paid or incurred during the tax year.

  • MRD: Companies that spent over $5 million on qualified R&D expenses could apply to receive the nonrefundable MRD tax credit and offset a maximum of 75% of their taxable income. The MRD credit percentage was equivalent to 10% of the company’s QREs and any unused credits could be carried forward for up to 10 years.
  • RDC: Companies that spent $5 million or less on qualified R&D activities could apply for the RDC, a refundable incentive that was equivalent to 15% of the first $300,000 incurred in the tax year, up to an annual limit of $45,000. Any amount excess of that limit was paid to the taxpayer as a refund.

New Legislation

For tax years beginning on or after January 1, 2023, but before January 1, 2025, both R&D tax credits can now be applied against the corporate income tax, individual income tax, or bank franchise tax. 

For the RDC Credit, the aggregate credit cap has risen from $7.77 million to $15.77 million. 

For the MRD Credit, the credit rate changed from 10% to a step-rate style. The first $1 million is calculated with a 10% rate while the following $2-5 million uses 5%. In addition, a new application amount cap of $300,000 has been applied where previously there was no cap at all. The MRD aggregate credit cap has reduced from $24 million to $16 million.

Impacts

Taxpayers claiming the RDC credit have no changes to the underlying mechanics of the calculation. However, the credit pool has doubled which means that taxpayers who apply through this category will likely see a significantly higher credit than in prior years, up to (or even over) the $45,000 cap.

For taxpayers historically claiming the MRD credit in significant excess of $300,000, the new application cap will immediately cut the size of their applications. And then the 33 percent reduction in the overall credit pool will further limit their benefit. 

Those who apply for the MRD near or below $300,000 will only be affected by the reduced aggregate credit cap.

Companies should consider both methods, if eligible for either, and prepare their tax returns and applications accordingly. One noteworthy feature of Virginia’s R&D tax credit regime is that although the MRD credit has a $5 million QRE requirement, there is no corresponding qualified research expenditures (QRE) requirement for the RDC credit. Thus, although the law prevents taxpayers from claiming both credits, a taxpayer that qualifies for the MRD credit could elect to apply under either regime.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Revolutionizing the EV Industry: Fermi Energy’s Coal-Based Solution

ECED Breaks Ground for Coal-Based Innovation

In a world that is increasingly shifting towards sustainable energy solutions, the electric vehicle (EV) industry stands at the forefront of innovation. One company that is making significant strides in this arena is Fermi Energy, Inc.. This trailblazing firm is revolutionizing the U.S. battery manufacturing industry with its advanced cathode technologies, all while maintaining a commitment to economic and environmental sustainability.

Fermi Energy is not just another player in the battery game; it is a pioneer in the field. The company’s mission is clear: to power electric vehicles with locally sourced materials, including one surprising ingredient—coal. Yes, you read that right—coal, a material often associated with pollution and environmental concerns, is being repurposed for a cleaner, greener future.

Fermi Energy has received significant grant funding this year, including a $2.9 million grant from the U.S. Department of Energy and a $3.4 million award in collaboration with General Motors and other companies. These grants will support the development of batteries with coal-derived anodes, which can address environmental issues associated with coal waste and significantly reduce anode costs compared to traditional graphite anodes.

By tapping into innovative materials selection and groundbreaking processing technologies, Fermi Energy has managed to reduce cathode costs by an impressive 50%. This significant cost reduction is a game-changer in the EV industry, making electric vehicles more affordable and accessible for the masses. It’s not just a win for consumers; it’s a win for the planet.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Strivacity Secures $20M in Series A Funding

software

Virginia-based startup, Strivacity, Inc., has secured $20 million in a Series A-2 funding round.

The round was led by SignalFire with participation from Ten Eleven Ventures, Mandiant founder Kevin Mandia, and Tenable co-founder Jack Huffard. The fresh cash brings Strivacity’s total raised to $28 million, which Graham, Strivacity’s CEO, says is being put toward product R&D, various go-to-market initiatives and customer support.

The company is tackling the growing challenges around authentication. Identity and access security issues are increasingly top of mind for companies. The startup allows companies to create secure business-to-business and business-to-consumer sign-in experiences. 

With Strivacity’s platform, users get access to a dashboard with radio buttons and drop-down menus they can use to create sign-in flows. Strivacity handles aspects like consent management, identity verification and branding. And because it’s hosted on a scalable cloud, it can ramp up to match spikes in customer login activity for up to hundreds of millions of monthly active users. 

The platform is further equipped with AI and machine learning models to bar bots from logging in and stealing data. The models look at customer behavior and usage patterns to identify any unusual activity when compared against a user’s history. When something anomalous happens, additional security steps are triggered to protect a user’s account from being hijacked.

Upcoming R&D will focus on adding new features including document-based verification and support for companies with multiple subsidiaries and divisions. In the next 12 months, Strivacity plans to nearly double its workforce from 40 employees to around 70.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Virongy Expands Focus Beyond HIV and COVID-19

hospital-1802679_1920

Virongy, a Virginia biotech company, intends to expand their scope beyond their HIV and COVID-19 research. With millions of people being afflicted by viral illnesses worldwide each year, Virongy’s objective addresses an ever-increasing market need.

“Our goal is to create advanced diagnostics so that doctors can promptly prescribe treatments to patients,” said Brian Hetrick, chief scientific officer of Virongy.

The company already made striking advancements in HIV and COVID-19 research through the development of virological reagents and tools. These developments include:

  • HIV Rev-dependent Lentiviral Vector
    • Able to selectively express therapeutic genes only in HIV-infected cells, providing the potential to develop therapeutic vaccines to target HIV reservoirs
  • HIV Rev-dependent Reporter Cells
    • State-of-the-art HIV-indicator cells. The incredibly high specificity and accuracy in quantifying HIV infection improves anti-HIV drug screening, antibody screening, and anti-HIV compound screening. 
  • Ha-CoV-2 and Ha-CoV-2 Variants
    • Ha-CoV-2 represents a major technology advancement in the development of SARS-CoV-2 pseudoviruses, and serves as platforms for rapid and robust quantification of neutralizing antibodies, viral mutants, and antiviral drugs.

To support this growing scope of focus, Virongy has moved to a 1,600 sq ft bioscience lab within the new Northern Virginia Bioscience Center. Next steps include obtaining Good Manufacturing Practices (GMP) certification in order to open a GMP lab. The certification ensures that all products produced in the lab are safe and effective, as well as expedites the FDA approval process for any products the company intends to bring to market. Virongy anticipates having GMP certification within the next several months.

Are you developing new biotechnology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Second Genome Collaborates with VCU to Develop Diagnostic Biomarker for NASH

hospice-4135835_1920-1

Second Genome is a tech-enabled biotech company that extracts microbial genetic insights to guide their transformational precision therapies and biomarkers. They find these insights using their proprietary platform – sg-4sight. Recently, they have announced a research collaboration with Virginia Commonwealth University (VCU) as they work to generate a non-invasive stool-based composite biomarker for non-alcoholic steatohepatitis (NASH). 

Second Genome will use their sg-4sight discovery engine’s machine learning capabilities to identify composite biomarkers that can diagnose patients with NASH who have advanced fibrosis. This will require the characterization of the GI microbial taxa and microbial transcriptome in NASH. They will also characterize these taza in non-alcoholic fatty liver disease (NAFLD) patients. VCU’s Dr. Arun Sanyal, a professor of Medicine, Physiology, and Molecular Pathology, will provide geographically diverse patient samples, clinical meta-data, liver biopsy images and a biorepository. Once Second Genome identifies the biomarker, the model will be clinically validated in patients enrolled in the VCU biorepository.

The present gold standard diagnosis for patients living with NASH is a highly invasive liver biopsy with critical side effects. Dr. Sanyal says there is a significant need to advance non-invasive diagnostic approaches and believes Second Genome’s machine learning capabilities and microbial expertise will be key to developing a non-invasive diagnostic marker. 

Are you developing new biotechnology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Alquist 3D to Test Additive Construction of Homes

Alquist 3D, an additive construction company,  is focused on solving America’s housing shortage crisis. Their method involves designing dream homes at genuinely affordable prices. They have teamed up with the Virginia Center for Housing Research (VCHR) at Virginia Tech to design, build, and study a 3D-printed single family home – the first of its kind in the United States. This step has been made possible through a $500,000 Innovation Demonstration Grant from Virginia Housing.

The grant provided the funding to purchase a modular 3D printer – the BOD2 – which can be assembled in a matter of hours and requires just two construction workers to be present on-site during operation. This first test will be constructed using a concrete mix, but the open-source nature of the system means future homes can be constructed from more sustainable materials. This test run will print the exterior walls of a 1,550 sq ft, three-bedroom bungalow.

With the use of concrete, Alquist predicts initial savings of up to 15 percent-per-square-foot of building. Classic stick-built homes are facing massive cost increases as the pandemic has led to soaring lumber prices. The speed and efficiency of additive construction would only further reduce these costs and could produce a brand new home in 12 to 15 hours. Virginia Tech has built a proprietary Raspberry Pi-based smart home monitoring system that will be built into Alquist-built dwellings to monitor the indoor environment sensing (air quality, temperature, humidity etc.). This sensing system can contribute to long-term cost savings and efficiencies throughout owning the home. 

Alquist is focused on applying this technology and these houses to build homes for people who live outside of the places where most funding for housing programs is spent. This focus is largely in rural areas, with a target construction price for similar style homes at $181,000.

Are you developing new technology for a new application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Two Six Technologies Announces Bob Kwaja as New CFO

laptop-2561221_1920

Two Six Technologies has announced Bob Kwaja as their new Chief Financial Officer. Kwaja brings an established track record in financial strategy and operations for private equity-owned, high-growth government technology companies, and will play a vital role in accelerating Two Six Technologies’ strategic growth in the sector. 

Two Six Technologies is newly formed by the combining of IST Research and Two Six Labs. This new company will be a high-growth, technology-focused provider to the Intelligence Community, Department of Defense, and other critical U.S. national security customers. IST Research is a leading provider of open source data collection, population engagement, and content discovery solutions primarily for U.S. Government customers. Two Six Labs is a leading provider of cybersecurity and advanced technology solutions for the U.S. Government. As a combined force they intend to deliver R&D, innovation, productization and implementation expertise in cyber, data science, mobile, microelectronics and information operations.

“Joining this newly formed platform is an inspiring opportunity,” said Kwaja. “Two Six Technologies possesses an exceptional management team, the backing of The Carlyle Group— one of the most accomplished private equity firms in the world—and a board of respected industry leaders. I look forward to working with the team to execute on the company’s growth trajectory and strategic vision.”

Are you developing new technology for a new application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Advance Energy Expands for Solar and Wind Farm Manufacturing

Advance Energy Expands for Solar and Wind Farm Manufacturing

Advance Energy Solutions, Inc has purchased an old water plant facility in Ridgeway, Virginia with the intention of converting the space into a control panel assembly plant. The control panels belong to their Solar and Wind Farm equipment which services manufacturers and developers in Virginia and North Carolina.

Advance Energy focuses their research and development on creating smart grid solutions, energy monitoring systems, and micro-grid integrators for solar and wind farms. They partner with Sunstream to provide portable solar panels for instant charging of outdoor recreational devices and cell phones while hiking, boating, fishing or camping.

Their new location will allow them the opportunity to expand their research and development on their solar and wind control panels as well as other upcoming projects. The proximity to Virginia Tech’s Electrical Engineering Department will open them up to using the student talent to help grow their operations and expand their clean energy development.

Are you developing new technology? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.